KCA
Search
- Page Path
- HOME > Search
Original Articles
- Lung and Thoracic cancer
- Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non–Small Cell Lung Cancer
- Hanbaek Yi, Jeonghwan Youk, Yoojoo Lim, Hanseong Roh, Dongsoo Kyung, Hwang-Phill Kim, Duhee Bang, Bhumsuk Keam, Tae-Min Kim, Miso Kim, Dong-Wan Kim, Tae-You Kim
- Cancer Res Treat. 2024;56(3):765-773. Published online January 8, 2024
- DOI: https://doi.org/10.4143/crt.2023.1294
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)–based circulating tumor DNA (ctDNA) assay.
Materials and Methods
Analytical validation was conducted in vitro by evaluating the limit of detection (LOD), precision, and specificity for various genomic aberrations. The real-world performance in non–small cell lung cancer (NSCLC) was assessed by comparing the results of AlphaLiquid100 to the tissue-based results.
Results
The LODs with 30 ng input DNA were 0.11%, 0.11%, 0.06%, 0.21%, and 2.13 copies for detecting single nucleotide variants, insertions, deletions, fusions, and copy number alterations (CNA), respectively. Quantitatively, single nucleotide variants/insertions and deletions, fusions, and CNAs showed a good correlation (R2=0.91, 0.40, and 0.65; y=0.95, 1.06, and 1.19) to the manufacturer’s values, and per-base specificities for all types of variants were near 100%. In real-world NSCLC (n=122), key actionable mutations in NSCLC were detected in 60.7% (74/122) with the ctDNA assay. Comparative analysis against the NGS-based tissue results for all key mutations showed positive percent agreement (PPA) of 85.3%. For individual genes, the PPA was as high as 95.7% for epidermal growth factor receptor (EGFR) mutations and 83.3% for ALK translocations. AlphaLiquid100 detected drug-sensitive EGFR mutation at a variant allele frequency as low as 0.02% and also identified an EGFR mutation in a case where tissue sample missed. Blood samples collected post-targeted therapies revealed additional acquired mutations.
Conclusion
The AlphaLiquid100 ctDNA assay demonstrates robust analytical validity, offering clinically important information for NSCLC patients. -
Citations
Citations to this article as recorded by
- Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop
Vincent D. de Jager, Patrizio Giacomini, Jennifer A. Fairley, Rodrigo A. Toledo, Simon J. Patton, Simon A. Joosse, Claudia Koch, Zandra C. Deans, Sofia Agelaki, Claus Lindbjerg Andersen, Daniel Andersson, Beatriz Bellosillo, Inger Riise Bergheim, Daan van
eBioMedicine.2025; 114: 105636. CrossRef - Next-generation sequencing impact on cancer care: applications, challenges, and future directions
Mariano Zalis, Gilson Gabriel Viana Veloso, Pedro Nazareth Aguiar Jr., Nathalia Gimenes, Marina Xavier Reis, Silvio Matsas, Carlos Gil Ferreira
Frontiers in Genetics.2024;[Epub] CrossRef - Profiling Cell-Free DNA from Malignant Pleural Effusion for Oncogenic Driver Mutations in Patients with Treatment-Naive Stage IV Adenocarcinoma: A Multicenter Prospective Study
Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen, Yi-Chun Lai, Po-Wei Hu, Jui-Chi Hung, Cheng-Yu Chang
Molecular Diagnosis & Therapy.2024; 28(6): 803. CrossRef - Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon
Journal of Hepatology.2024;[Epub] CrossRef
- Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop
- 5,822 View
- 374 Download
- 3 Web of Science
- 4 Crossref
- Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
- Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo
- Cancer Res Treat. 2017;49(2):416-422. Published online July 28, 2016
- DOI: https://doi.org/10.4143/crt.2016.121
-
Abstract
PDFPubReaderePub
- Purpose
The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer.
Materials and Methods
Patients were treated with irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity.
Results
A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the perprotocol group was 30.0% (90% confidence interval [CI], 13.2 to 46.9). The median follow-up duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%).
Conclusion
Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer. -
Citations
Citations to this article as recorded by- Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef - Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
Xichao Dai, Leilei Tao, Jinqiu Wang, Wenjuan Wu, Weigang Bian, Xichun Dai, Surong Chen
Cancer Medicine.2023; 12(15): 16108. CrossRef - Cisplatin-based combination therapy for cancer
Minerva, Amrita Bhat, Sonali Verma, Gresh Chander, Rajeshwer Singh Jamwal, Bhawani Sharma, Audesh Bhat, Taruna Katyal, Rakesh Kumar, Ruchi Shah
Journal of Cancer Research and Therapeutics.2023; 19(3): 530. CrossRef - The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
Seminars in Cancer Biology.2022; 86: 873. CrossRef - Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
Zhihuang Hu, Si Sun, Xinmin Zhao, Hui Yu, Xianghua Wu, Jialei Wang, Jianhua Chang, Huijie Wang
The Oncologist.2022; 27(4): 253. CrossRef - Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
Tianhui Wei, Wenqi Ti, Qingxu Song, Yufeng Cheng
Current Oncology.2022; 29(5): 2920. CrossRef - Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells
Laura Valdez, Benxu Cheng, Daniela Gonzalez, Reanna Rodriguez, Paola Campano, Andrew Tsin, Xiaoqian Fang
Oncotarget.2022; 13(1): 642. CrossRef - Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect
Jiyun Lee, Binnari Kim, Hyun Ae Jung, Yoon La Choi, Jong-Mu Sun
Cancer Immunology, Immunotherapy.2021; 70(5): 1203. CrossRef - Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Paul B Tchounwou, Shaloam Dasari, Felicite K Noubissi, Paresh Ray, Sanjay Kumar
Journal of Experimental Pharmacology.2021; Volume 13: 303. CrossRef - SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
Thoracic Cancer.2021; 12(9): 1373. CrossRef - Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer
Mahsa Shahriari, Seyed Mohammad Taghdisi, Khalil Abnous, Mohammad Ramezani, Mona Alibolandi
Journal of Controlled Release.2021; 335: 369. CrossRef - Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
Min Liu, Qingqing Jia, Xiaolin Wang, Changjiang Sun, Jianqi Yang, Yanliang Chen, Ying Li, Lingfeng Min, Xizhi Zhang, Caiyun Zhu, Johannes Artiaga Gubat, Yong Chen
Anti-Cancer Drugs.2020; 31(4): 403. CrossRef - Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT‐11‐Induced Diarrhea in Mice
Jinhua Lu, Zechen Lin, Siyu Huang, Yiwei Shen, Jing Jiang, Shengyou Lin, Oliver Micke
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef - Treatment of esophageal cancer with multiple liver metastases: a case experience of sustained complete response
Jiangfang Wang, Chaoyang Xu
Journal of International Medical Research.2020;[Epub] CrossRef - Development of chemotherapeutics for unresectable advanced esophageal cancer
Hiroshi Imazeki, Ken Kato
Expert Review of Anticancer Therapy.2020; 20(12): 1083. CrossRef - Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai, Jing Huang
Cancer Communications.2020; 40(12): 711. CrossRef - Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
Hidekazu Hirano, Ken Kato
Japanese Journal of Clinical Oncology.2019; 49(5): 412. CrossRef - Carboxylesterase and UDP‐glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra‐performance liquid chromatography–mass spectrometry analysis
Yifeng Qin, An Kang, Guisheng Zhou, Huan Wang, Wei Wei, Yujie Cao, Yanyan Chen, Jing Wang, Yajun Shi, Yuping Tang, Jianqin Jiang
Biomedical Chromatography.2018;[Epub] CrossRef - A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. N
Biochemical and Biophysical Research Communications.2018; 505(3): 733. CrossRef - Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy
Yi-Han Chiu, Shih-Hsien Hsu, Hsiao-Wei Hsu, Kuo-Chin Huang, Wangta Liu, Chang-Yi Wu, Wei-Pang Huang, Jeff Chen, Bing-Hung Chen, Chien-Chih Chiu
International Journal of Oncology.2018;[Epub] CrossRef - ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PNCA
Xin-Fang Hou, Lin-Ping Xu, Hai-Yan Song, Shuai Li, Chen Wu, Ju-Feng Wang
World Journal of Gastroenterology.2017; 23(10): 1796. CrossRef - Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer
Bin Wei, Jiru Wang, Xiaohui Zhang, Zhaoye Qian, Jingjing Wu, Yuan Sun, Qin Han, Li Wan, Jing Zhu, Yong Gao, Xiaofei Chen
Oncology Letters.2017;[Epub] CrossRef
- Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
- 12,181 View
- 272 Download
- 27 Web of Science
- 22 Crossref
- Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
- Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo
- Cancer Res Treat. 2017;49(1):129-140. Published online May 18, 2016
- DOI: https://doi.org/10.4143/crt.2015.466
-
Abstract
PDFPubReaderePub
- Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival. -
Citations
Citations to this article as recorded by- The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
Biomedicines.2022; 10(6): 1285. CrossRef - Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
Diagnostics.2022; 12(12): 3120. CrossRef - Identification of diverse tumor endothelial cell populations in malignant glioma
Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
Neuro-Oncology.2021; 23(6): 932. CrossRef - Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
Journal of Neuro-Oncology.2018; 138(1): 141. CrossRef
- The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
- 10,520 View
- 181 Download
- 5 Web of Science
- 4 Crossref
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- Do-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Bang
- Cancer Res Treat. 2015;47(4):607-615. Published online February 26, 2015
- DOI: https://doi.org/10.4143/crt.2014.249
-
Abstract
PDFPubReaderePub
- Purpose
OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received OPB-31121 once daily for 28 days of each cycle followed by 2 weeks rest. A standard 3+3 design was used for dose-escalation. Safety and response were evaluated by the National Cancer Institute–Common Terminology Criteria for Adverse Events (NCICTCAE) ver. 3.0 and Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.0, respectively.
Results
Twenty-five patients were treated with OPB-31121 at five dose levels: 100 mg (n=4), 200 mg (n=3), 400 mg (n=3), 600 mg (n=7), and 800 mg (n=8). Seven patients discontinued treatment during cycle 1 for various reasons other than study drug-related adverse events. Among 18 patients who were evaluable for dose-limiting toxicity (DLT), three DLTs were observed: one DLT (grade 3 vomiting) at 600 mg and two DLTs (grade 3 vomiting, grade 3 diarrhea) at 800 mg. The MTD was determined as 800 mg/day. Common adverse events were gastrointestinal adverse event including nausea (84%), vomiting (80%), and diarrhea (72%). Pharmacokinetics did not demonstrate dose-proportionality of OPB-31121. Eight patients had stable disease and 10 patients had disease progression. Two patients (1 colon cancer, 1 rectal cancer) showed tumor shrinkage. One gastric cancer patient continued treatment up to cycle 13 before disease progression. Conclusion This study demonstrates feasibility of STAT3 inhibition in patients with advanced solid tumor. OPB-31121, at the MTD of 800 mg/day, was safe and relatively well tolerated, and has a preliminary antitumor activity. -
Citations
Citations to this article as recorded by- Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria
Sahar Rastgoo, Mojgan Mohammadi, Marcus Maurer, Mahdi Atabaki, Jalil Tavakkol-Afshari, Maryam Khoshkhui
Clinical and Experimental Dermatology.2025; 50(2): 357. CrossRef - Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy
Win Lwin Thuya, Yang Cao, Paul Chi-Lui Ho, Andrea Li-Ann Wong, Lingzhi Wang, Jianbiao Zhou, Christophe Nicot, Boon Cher Goh
Cytokine & Growth Factor Reviews.2025;[Epub] CrossRef - CTSL Promotes Autophagy in Laryngeal Cancer Through the IL6‐JAK‐STAT3 Signalling Pathway
Xueying Wang, Junrong Wang, Lei Wang, Ming Song, Hongxue Meng, Erliang Guo, Susheng Miao
Journal of Cellular and Molecular Medicine.2025;[Epub] CrossRef - Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef - STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, Te Zhang, Xuming Song, Hanling Ding, Rutao Li, Yijian Zhang, Zi Wang, Hui Wang, Wenjie Xia, Lei Wei, Lin Xu, Gaochao Dong, Feng Jiang
Cancer Science.2025;[Epub] CrossRef - STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Zoe King, Sudhamsh Reddy Desai, David A. Frank, Aditi Shastri
Neoplasia.2025; 61: 101137. CrossRef - Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Yamei Hu, Zigang Dong, Kangdong Liu
Journal of Experimental & Clinical Cancer Research.2024;[Epub] CrossRef - Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Greta Pessino, Claudia Scotti, Maristella Maggi
Cancers.2024; 16(5): 901. CrossRef - Impact of STAT-signaling pathway on cancer-associated fibroblasts in colorectal cancer and its role in immunosuppression
Damián Sánchez-Ramírez, Mónica G Mendoza-Rodríguez, Omar R Alemán, Fernando A Candanedo-González, Miriam Rodríguez-Sosa, Juan José Montesinos-Montesinos, Mauricio Salcedo, Ismael Brito-Toledo, Felipe Vaca-Paniagua, Luis I Terrazas
World Journal of Gastrointestinal Oncology.2024; 16(5): 1705. CrossRef - Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Julia Martínez-Pérez, Carlos Torrado, María A. Domínguez-Cejudo, Manuel Valladares-Ayerbes
International Journal of Molecular Sciences.2024; 25(11): 6220. CrossRef - Interleukin-6 serves as a critical factor in various cancer progression and therapy
Asma’a H. Mohamed, Abdulrahman T. Ahmed, Waleed Al Abdulmonem, Dmitry Olegovich Bokov, Alaa Shafie, Hussein Riyadh Abdul Kareem Al-Hetty, Chou-Yi Hsu, Mohammed Alissa, Shahid Nazir, Mohammad Chand Jamali, Mustafa Mudhafar
Medical Oncology.2024;[Epub] CrossRef - Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef - Recent advances in targeted drug delivery systems for multiple myeloma
Ashruti Pant, Aayushi Laliwala, Sarah A. Holstein, Aaron M. Mohs
Journal of Controlled Release.2024; 376: 215. CrossRef - A strategic review of STAT3 signaling inhibition by phytochemicals for cancer prevention and treatment: Advances and insights
Suryaa Manoharan, Ekambaram Perumal
Fitoterapia.2024; 179: 106265. CrossRef - The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
Mengxuan Zhu, Suyao Li, Xin Cao, Khalid Rashid, Tianshu Liu
Seminars in Cancer Biology.2023; 88: 18. CrossRef - Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
Xiaoqing Guan, Jing Yang, Weiyi Wang, Bing Zhao, Shiyu Hu, Dehua Yu, Li Yuan, Yunfu Shi, Jingli Xu, Jinyun Dong, Jinxin Wang, Xiang-Dong Cheng, Jiang-Jiang Qin
Pharmacological Research.2023; 189: 106703. CrossRef - JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Qian Hu, Qihui Bian, Dingchao Rong, Leiyun Wang, Jianan Song, Hsuan-Shun Huang, Jun Zeng, Jie Mei, Peng-Yuan Wang
Frontiers in Bioengineering and Biotechnology.2023;[Epub] CrossRef - Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay
Xueying Fan, Mingjing Meng, Baoting Li, Hui Chen, Jincheng Tan, Keyang Xu, Shilin Xiao, Hiu-Yee Kwan, Zhongqiu Liu, Tao Su
Journal of Translational Medicine.2023;[Epub] CrossRef - Application of Nano-Antibodies for Cancer Immunotherapy
Sunanda Singh, Samara P. Singh, Ashutosh S. Parihar
Current Tissue Microenvironment Reports.2023; 4(2): 17. CrossRef - Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu, Lili Yang
Journal of Translational Medicine.2023;[Epub] CrossRef - C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice
Yuko Ono, Masafumi Saito, Kazuho Sakamoto, Yuko Maejima, Shingen Misaka, Kenju Shimomura, Nobuto Nakanishi, Shigeaki Inoue, Joji Kotani
Frontiers in Pharmacology.2022;[Epub] CrossRef - Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer
Madhuvanthi Giridharan, Vasu Rupani, Satarupa Banerjee
ACS Pharmacology & Translational Science.2022; 5(4): 193. CrossRef - Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, Weimin Yi, Chuang Peng, Sulai Liu
Molecular Medicine Reports.2022;[Epub] CrossRef - Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
Redox Biology.2022; 52: 102317. CrossRef - Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Yanhong Ni, Jun T. Low, John Silke, Lorraine A. O’Reilly
Frontiers in Immunology.2022;[Epub] CrossRef - A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
Sunanda Singh, Genoveva Murillo, Justin Richner, Samara P. Singh, Erica Berleth, Vijay Kumar, Rajendra Mehta, Vijay Ramiya, Ashutosh S. Parihar
International Journal of Molecular Sciences.2022; 23(14): 7565. CrossRef - Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy
Elham Patrad, Solmaz Khalighfard, Taghi Amiriani, Vahid Khori, Ali Mohammad Alizadeh
Cellular Oncology.2022; 45(6): 1073. CrossRef - STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma
Mingjing Jiang, Bo Li
Cells.2022; 11(19): 3131. CrossRef - The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities
Magdalena Rašková, Lukáš Lacina, Zdeněk Kejík, Anna Venhauerová, Markéta Skaličková, Michal Kolář, Milan Jakubek, Daniel Rosel, Karel Smetana, Jan Brábek
Cells.2022; 11(22): 3698. CrossRef - An update on investigational therapies that target STAT3 for the treatment of cancer
Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
Expert Opinion on Investigational Drugs.2021; 30(3): 245. CrossRef - RETRACTED: GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models
Sun Young Moon, Kwang Dong Kim, Jiyun Yoo, Jeong-Hyung Lee, Cheol Hwangbo
Molecules.2021; 26(9): 2824. CrossRef - Development and Validation of an IL6/JAK/STAT3-Related Gene Signature to Predict Overall Survival in Clear Cell Renal Cell Carcinoma
Chuanchuan Zhan, Chao Xu, Jiajun Chen, Chong Shen, Jinkun Li, Zichu Wang, Xiangrong Ying, Zhengang Luo, Yu Ren, Gangfeng Wu, Haojie Zhang, Manfei Qian
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas
Cyndy Liu, Tae Nakano-Tateno, Motoyasu Satou, Constance Chik, Toru Tateno
Endocrine Journal.2021; 68(10): 1143. CrossRef - The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao, Wei Wang
Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef - Interleukin-6 and colorectal cancer development
I.А. Hromakova, P.P. Sorochan, N.E. Prokhach, I.S. Hromakova
Український радіологічний та онкологічний журнал.2021; 29(4): 89. CrossRef - Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway
Haixiang Ding, Xiuchong Yu, Zhilong Yan
International Journal of Molecular Medicine.2021;[Epub] CrossRef - Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells
Kimberly M. Arnold, Lynn M. Opdenaker, Nicole J. Flynn, Daniel Kwesi Appeah, Jennifer Sims-Mourtada
International Journal of Radiation Biology.2020; 96(4): 434. CrossRef - Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization
Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini
Journal of the American Chemical Society.2020; 142(6): 2876. CrossRef - Phosphotyrosine isosteres: past, present and future
Robert A. Cerulli, Joshua A. Kritzer
Organic & Biomolecular Chemistry.2020; 18(4): 583. CrossRef - Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1
Hai Zhang, Yu-ping Tan, Lin Zhao, Lun Wang, Nai-jie Fu, Song-ping Zheng, Xiao-fei Shen
Cell Death & Disease.2020;[Epub] CrossRef - JAK/STAT signaling in hepatocellular carcinoma
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
Hepatic Oncology.2020;[Epub] CrossRef - JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
Nature Reviews Gastroenterology & Hepatology.2020; 17(6): 323. CrossRef - Targeting STAT3 in cancer and autoimmune diseases
Tohid Gharibi, Zohreh Babaloo, Arezoo Hosseini, Meghdad Abdollahpour-alitappeh, Vida Hashemi, Faroogh Marofi, Kazem Nejati, Behzad Baradaran
European Journal of Pharmacology.2020; 878: 173107. CrossRef - Betacellulin drives therapy resistance in glioblastoma
Qiwen Fan, Zhenyi An, Robyn A Wong, Xujun Luo, Edbert D Lu, Albert Baldwin, Manasi K Mayekar, Franziska Haderk, Kevan M Shokat, Trever G Bivona, William A Weiss
Neuro-Oncology.2020; 22(4): 457. CrossRef - A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction
Soo Kyung Park, Woong Sub Byun, Seungbeom Lee, Young Taek Han, Yoo-Seong Jeong, Kyungkuk Jang, Suk-Jae Chung, Jeeyeon Lee, Young-Ger Suh, Sang Kook Lee
Biochemical Pharmacology.2020; 178: 114053. CrossRef - STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
Biology.2020; 9(6): 126. CrossRef - Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
Matteo Mori, Ettore Gilardoni, Luca Regazzoni, Alessandro Pedretti, Diego Colombo, Gary Parkinson, Akira Asai, Fiorella Meneghetti, Stefania Villa, Arianna Gelain
Molecules.2020; 25(15): 3509. CrossRef - STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
Ping-Lian Yang, Lu-Xin Liu, En-Min Li, Li-Yan Xu
Cancers.2020; 12(9): 2459. CrossRef Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer
Yan Lin, Ziqin He, Jiazhou Ye, Ziyu Liu, Xiaomin She, Xing Gao, Rong Liang
OncoTargets and Therapy.2020; Volume 13: 13023. CrossRef- Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
Chen-Hao Zhang, Ming Li, You-Pei Lin, Qiang Gao
Current Gene Therapy.2020; 20(2): 84. CrossRef - Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai
Cancers.2019; 11(2): 248. CrossRef - Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
Changhoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo
Cancer Research and Treatment.2019; 51(2): 510. CrossRef - IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1471. CrossRef - Proton pump inhibitor: The dual role in gastric cancer
Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
World Journal of Gastroenterology.2019; 25(17): 2058. CrossRef - Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
Gianluca Civenni, Domenico Albino, Dheeraj Shinde, Ramiro Vázquez, Jessica Merulla, Aleksandra Kokanovic, Sarah N. Mapelli, Giuseppina M. Carbone, Carlo V. Catapano
Frontiers in Oncology.2019;[Epub] CrossRef - STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Jiang-Jiang Qin, Li Yan, Jia Zhang, Wei-Dong Zhang
Journal of Experimental & Clinical Cancer Research.2019;[Epub] CrossRef - JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
Emily A. Irey, Chelsea M. Lassiter, Nicholas J. Brady, Pavlina Chuntova, Ying Wang, Todd P. Knutson, Christine Henzler, Thomas S. Chaffee, Rachel I. Vogel, Andrew C. Nelson, Michael A. Farrar, Kathryn L. Schwertfeger
Proceedings of the National Academy of Sciences.2019; 116(25): 12442. CrossRef - Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival
Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy
Journal of Advanced Research.2019; 20: 105. CrossRef - Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells
Liang Zhang, Timothy E. Peterson, Victor M. Lu, Ian F. Parney, David J. Daniels, Ilya Ulasov
PLOS ONE.2019; 14(7): e0220569. CrossRef - Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis
Yali Li, Cailing Gan, Yange Zhang, Yan Yu, Chen Fan, Yuanle Deng, Qianyu Zhang, Xi Yu, Yiwen Zhang, Liqun Wang, Fang He, Yongmei Xie, Tinghong Ye, Wenya Yin
Frontiers in Pharmacology.2019;[Epub] CrossRef - Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status
Tadashi Ashizawa, Akira Iizuka, Chie Maeda, Emiko Tanaka, Ryota Kondou, Haruo Miyata, Takashi Sugino, Takuya Kawata, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Akira Asai, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
Immunology Letters.2019; 216: 43. CrossRef - Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
Arianna Gelain, Matteo Mori, Fiorella Meneghetti, Stefania Villa
Current Medicinal Chemistry.2019; 26(27): 5165. CrossRef - The effects of signal transducer and activator of transcription three mutations on human platelets
Floor E. Aleva, Frank L. van de Veerdonk, Yang Li, Rahajeng N. Tunjungputri, Sami Simons, Philip G. De Groot, Mihai M. Netea, Yvonne F. Heijdra, Quirijn de Mast, André J.A.M. van der Ven
Platelets.2018; 29(6): 602. CrossRef - Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models
Won Gu Kim, Sheue-yann Cheng
Hormones and Cancer.2018; 9(2): 108. CrossRef - Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson, Rachel A. O'Keefe, Jennifer R. Grandis
Nature Reviews Clinical Oncology.2018; 15(4): 234. CrossRef - Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells
Sung Ho Kim, Hyo Soon Yoo, Moon Kyung Joo, Taehyun Kim, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun, Sang Woo Lee, Young-Tae Bak
BMC Cancer.2018;[Epub] CrossRef - Linker Variation and Structure–Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors
Francisco Lopez-Tapia, Christine Brotherton-Pleiss, Peibin Yue, Heide Murakami, Ana Carolina Costa Araujo, Bruna Reis dos Santos, Erin Ichinotsubo, Anna Rabkin, Raj Shah, Megan Lantz, Suzie Chen, Marcus A. Tius, James Turkson
ACS Medicinal Chemistry Letters.2018; 9(3): 250. CrossRef - Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy
Mario M. Soldevilla, Fernando Pastor
Molecular Therapy.2018; 26(3): 675. CrossRef - Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Jenny D. Beebe, Jing-Yuan Liu, Jian-Ting Zhang
Pharmacology & Therapeutics.2018; 191: 74. CrossRef - Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence, John J O’Shea
Journal of Leukocyte Biology.2018; 104(3): 499. CrossRef - Targeting JAK-STAT signal transduction in IBD
Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen
Pharmacology & Therapeutics.2018; 192: 100. CrossRef - “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Emira Bousoik, Hamidreza Montazeri Aliabadi
Frontiers in Oncology.2018;[Epub] CrossRef - Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Megha Budhwani, Roberta Mazzieri, Riccardo Dolcetti
Frontiers in Oncology.2018;[Epub] CrossRef - STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
Ilenia Segatto, Gustavo Baldassarre, Barbara Belletti
International Journal of Molecular Sciences.2018; 19(9): 2818. CrossRef - Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
Masaki Miura, Takeshi Miyatsuka, Takehiro Katahira, Shugo Sasaki, Luka Suzuki, Miwa Himuro, Yuya Nishida, Yoshio Fujitani, Taka-aki Matsuoka, Hirotaka Watada
EBioMedicine.2018; 36: 358. CrossRef - Aptamer-iRNAs as Therapeutics for Cancer Treatment
Mario M. Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P. Menon, Fernando Pastor
Pharmaceuticals.2018; 11(4): 108. CrossRef - A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M
The Oncologist.2018; 23(6): 658. CrossRef - Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome
Konstantin Masliantsev, Baptiste Pinel, Anaïs Balbous, Pierre-Olivier Guichet, Gaëlle Tachon, Serge Milin, Julie Godet, Mathilde Duchesne, Antoine Berger, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon
Oncotarget.2018; 9(3): 3968. CrossRef - Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking
Wenying Yu, Chenglong Li, Wenda Zhang, Yuanzheng Xia, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, Lingyi Kong
Journal of Medicinal Chemistry.2017; 60(7): 2718. CrossRef - Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
npj Precision Oncology.2017;[Epub] CrossRef - Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
Davide Genini, Lara Brambilla, Erik Laurini, Jessica Merulla, Gianluca Civenni, Shusil Pandit, Rocco D'Antuono, Laurent Perez, David E. Levy, Sabrina Pricl, Giuseppina M. Carbone, Carlo V. Catapano
Proceedings of the National Academy of Sciences.2017;[Epub] CrossRef - Identification of novel small molecules that inhibit STAT3-dependent transcription and function
Iryna Kolosenko, Yasmin Yu, Sander Busker, Matheus Dyczynski, Jianping Liu, Martin Haraldsson, Caroline Palm Apergi, Thomas Helleday, Katja Pokrovskaja Tamm, Brent D. G. Page, Dan Grander, Aamir Ahmad
PLOS ONE.2017; 12(6): e0178844. CrossRef - Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia
Hui-Er Gao, Yue Sun, Ya-Hui Ding, Jing Long, Xiao-Lei Liu, Ming Yang, Qing Ji, Ying-Hui Li, Yue Chen, Quan Zhang, Ying-Dai Gao
Oncotarget.2017; 8(24): 38990. CrossRef - Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation
Verena Leidgens, Judith Proske, Lisa Rauer, Sylvia Moeckel, Kathrin Renner, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau, Corinna Seliger
Oncotarget.2017; 8(5): 8250. CrossRef - Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
Yu Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao, Shi-Guang Zhao, Mitsutoshi Nakada
Oncotarget.2017; 8(67): 111728. CrossRef - Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao, Huameng Li, Huey-Jen Lin, Shulin Yang, Jiayuh Lin, Guang Liang
Trends in Pharmacological Sciences.2016; 37(1): 47. CrossRef - Targeting transcription factor STAT3 for cancer prevention and therapy
Edna Zhi Pei Chai, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Chao Wang, Alan Prem Kumar, Ramar Perumal Samy, Lina H.K. Lim, Lingzhi Wang, Boon Cher Goh, Kwang Seok Ahn, Kam Man Hui, Gautam Sethi
Pharmacology & Therapeutics.2016; 162: 86. CrossRef - Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Chiara Lazzari, Alberto Verlicchi, Anastasios Gkountakos, Sara Pilotto, Mariacarmela Santarpia, Imane Chaib, Jose Luis Ramirez Serrano, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi, Filippo de Marinis, Peng Cao, Niki Karachaliou, Rafael Rosell
Pulmonary Therapy.2016; 2(1): 1. CrossRef - Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
Zilma Escobar, Anders Bjartell, Giacomo Canesin, Susan Evans-Axelsson, Olov Sterner, Rebecka Hellsten, Martin H Johansson
Journal of Medicinal Chemistry.2016; 59(10): 4551. CrossRef - A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
Andres Rojas, Pingyu Zhang, Ying Wang, Wai Chin Foo, Nina M. Muñoz, Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung, Boris Blechacz
Neoplasia.2016; 18(6): 371. CrossRef - Novel STAT 3 inhibitors for treating gastric cancer
Catherine Cafferkey, Ian Chau
Expert Opinion on Investigational Drugs.2016; 25(9): 1023. CrossRef - ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
I De Kouchkovsky, M Abdul-Hay
Blood Cancer Journal.2016; 6(7): e441. CrossRef - Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun
World Journal of Gastroenterology.2016; 22(19): 4638. CrossRef - Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
Malgorzata Szelag, Anna Piaszyk-Borychowska, Martyna Plens-Galaska, Joanna Wesoly, Hans A.R. Bluyssen
Oncotarget.2016; 7(30): 48788. CrossRef - Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt
Maximilian Niit, Victoria Hoskin, Esther Carefoot, Mulu Geletu, Rozanne Arulanandam, Bruce Elliott, Leda Raptis
Biomolecular Concepts.2015; 6(5-6): 383. CrossRef - Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma
Takuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okita
Hepatology Research.2015; 45(13): 1283. CrossRef - STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
Heng Yang, Takahiro Yamazaki, Federico Pietrocola, Heng Zhou, Laurence Zitvogel, Yuting Ma, Guido Kroemer
Cancer Research.2015; 75(18): 3812. CrossRef
- Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria
- 18,982 View
- 258 Download
- 97 Web of Science
- 98 Crossref
- Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
- Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang
- Cancer Res Treat. 2016;48(1):28-36. Published online February 23, 2015
- DOI: https://doi.org/10.4143/crt.2014.258
-
Abstract
PDFPubReaderePub
- Purpose
CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. Materials and Methods Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.
Results
Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). Conclusion This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks. -
Citations
Citations to this article as recorded by- First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
Xiao-Li Wei, Hao-Xiang Wu, Dan-Yun Ruan, Feng Wang, Li Xu, Yu-Hong Li, Yu-Xiang Ma, Zhi-Qiang Wang, Yun-Peng Yang, Liang-Wei Tang, Bao-Lin Chen, Zhi-Quan Yong, Rui-Hua Xu, Hong-Yun Zhao
Cell Reports Medicine.2025; 6(2): 101969. CrossRef - Natural‐Product‐Inspired Discovery of Trimethoxyphenyl‐1,2,4‐triazolosulfonamides as Potent Tubulin Polymerization Inhibitors
Vajja Krishna Rao, Anvesh Ashtam, Dulal Panda, Sankar K. Guchhait
ChemMedChem.2024;[Epub] CrossRef - Thiazole, Isatin and Phthalimide Derivatives Tested in vivo against
Cancer Models: A Literature Review of the Last Six Years
Aline Ferreira Pinto, Janine Siqueira Nunes, José Eduardo Severino Martins, Amanda Calazans Leal, Carla Cauanny Vieira Costa Silva, Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olímpio, Elineide Tayse Noberto da Silva, Thiers Araújo Camp
Current Medicinal Chemistry.2024; 31(20): 2991. CrossRef - CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer
Soo Jin Kim, Kyunghyeon Lee, Jaewoo Park, Miso Park, U. Ji Kim, Se-mi Kim, Keun Ho Ryu, Keon Wook Kang
Toxicological Research.2023; 39(1): 61. CrossRef - Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer
Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel
Journal of Drug Targeting.2021; 29(4): 430. CrossRef - A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim, Tae Won Kim
Investigational New Drugs.2021; 39(5): 1335. CrossRef - Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents
M. Shaheer Malik, Saleh A. Ahmed, Ismail I. Althagafi, Mohammed Azam Ansari, Ahmed Kamal
RSC Medicinal Chemistry.2020; 11(3): 327. CrossRef - Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus
Haiyang Yu, Na Shen, Yanli Bao, Li Chen, Zhaohui Tang
Biomaterials Science.2020; 8(1): 325. CrossRef - Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, Keun Ho Ryu, Seonghae Yoon, Yun Kim, Joo‐Youn Cho, Keun Seok Lee, Tak Yun, Kiwon Kim, Mi Hyang Kwak, Tae‐Sung Kim, Jinsoo Chung, Joong‐Won Park
Pharmacology Research & Perspectives.2020;[Epub] CrossRef - Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors
Mai F. Tolba
International Journal of Cancer.2020; 147(11): 2996. CrossRef - Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway
Jian Song, Qiu-Lei Gao, Bo-Wen Wu, Ting Zhu, Xin-Xin Cui, Cheng-Jun Jin, Shu-Yu Wang, Sheng-Hui Wang, Dong-Jun Fu, Hong-Min Liu, Sai-Yang Zhang, Yan-Bing Zhang, Yong-Chun Li
European Journal of Medicinal Chemistry.2020; 203: 112618. CrossRef - Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung, Jin-Hyoung Kang
BMC Cancer.2020;[Epub] CrossRef - Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors
Fang Yang, Cai-Ping He, Peng-Cheng Diao, Kwon Ho Hong, Jin-Jun Rao, Pei-Liang Zhao
Bioorganic & Medicinal Chemistry Letters.2019; 29(1): 22. CrossRef - Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Jason H. Gill, Kimberly L. Rockley, Carol De Santis, Asma K. Mohamed
Pharmacology & Therapeutics.2019; 202: 18. CrossRef - Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment
Na Shen, Jing Wu, Chenguang Yang, Haiyang Yu, Shengcai Yang, Tete Li, Jingtao Chen, Zhaohui Tang, Xuesi Chen
Nano Letters.2019; 19(11): 8021. CrossRef - Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site
Ling Li, Sibo Jiang, Xiaoxun Li, Yao Liu, Jing Su, Jianjun Chen
European Journal of Medicinal Chemistry.2018; 151: 482. CrossRef - Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
Ryszard Smolarczyk, Tomasz Cichoń, Ewelina Pilny, Magdalena Jarosz-Biej, Aleksandra Poczkaj, Natalia Kułach, Stanisław Szala
Scientific Reports.2018;[Epub] CrossRef - Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
In Joon Lee, Myungsu Lee, Soo Jin Kim, You Kyung Kim, Jong Yun Won, Jin Wook Chung
Journal of Vascular and Interventional Radiology.2018; 29(8): 1078. CrossRef - Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
Hepatology International.2017; 11(5): 446. CrossRef - Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali, Ritu Ojha, Hsueh-Yun Lee, Jing-Ping Liou
Expert Opinion on Investigational Drugs.2016; 25(8): 917. CrossRef - Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
María-Jesús Pérez-Pérez, Eva-María Priego, Oskía Bueno, Maria Solange Martins, María-Dolores Canela, Sandra Liekens
Journal of Medicinal Chemistry.2016; 59(19): 8685. CrossRef - Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis
Souvik Banerjee, Dong-Jin Hwang, Wei Li, Duane Miller
Molecules.2016; 21(11): 1468. CrossRef
- First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors
- 11,969 View
- 140 Download
- 22 Web of Science
- 22 Crossref
First
Prev
